(Q38089737)

28 August 2017

title

Antidiabetic agents: past, present and future (English)

1 reference

28 August 2017

Ahmed Mehanna

1

1 reference

28 August 2017

language of work or name

1 reference

1 March 2013

1 reference

Future Medicinal Chemistry

28 August 2017

published in

1 reference

28 August 2017

volume

5

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

411-430

1 reference

Cardiovascular complications in diabetes: lessons from animal models.

28 August 2017

cites work

1 reference

Cardiovascular complications of diabetes mellitus: The Tissue Factor perspective

21 January 2018

1 reference

Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update.

21 January 2018

1 reference

Molecular understanding of hyperglycemia's adverse effects for diabetic complications

21 January 2018

1 reference

p66(Shc) protein, oxidative stress, and cardiovascular complications of diabetes: the missing link.

21 January 2018

1 reference

Oxidative stress and aging: is methylglyoxal the hidden enemy?

21 January 2018

1 reference

Role of 14-3-3 protein and oxidative stress in diabetic cardiomyopathy

21 January 2018

1 reference

Erythrocyte oxidative stress in clinical management of diabetes and its cardiovascular complications

21 January 2018

1 reference

Role of oxidative stress in development of cardiovascular complications in diabetes mellitus.

21 January 2018

1 reference

Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients

21 January 2018

1 reference

Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association

21 January 2018

1 reference

Joint association of glycemic load and alcohol intake with type 2 diabetes incidence in women

21 January 2018

1 reference

Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.

21 January 2018

1 reference

Shift from surrogate end point to outcome trials: implications for cardiovascular safety assessment in development programs for antidiabetic drugs.

21 January 2018

1 reference

Type 1 diabetes: new perspectives on disease pathogenesis and treatment

21 January 2018

1 reference

Standards of medical care in diabetes--2012

21 January 2018

1 reference

Evaluation of guidelines on diabetes medication.

21 January 2018

1 reference

AMPK activators--potential therapeutics for metabolic and other diseases

21 January 2018

1 reference

Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13C-isotopomer-based metabolomics

21 January 2018

1 reference

Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk

21 January 2018

1 reference

Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators

21 January 2018

1 reference

Recent developments and biological activities of thiazolidinone derivatives: a review.

21 January 2018

1 reference

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

21 January 2018

1 reference

Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors

21 January 2018

1 reference

Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes.

21 January 2018

1 reference

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

GLP-1 based therapy for type 2 diabetes

21 January 2018

1 reference

Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus

21 January 2018

1 reference

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide

21 January 2018

1 reference

Liraglutide: from clinical trials to clinical practice

21 January 2018

1 reference

Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes

21 January 2018

1 reference

Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.

21 January 2018

1 reference

Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.

21 January 2018

1 reference

Pharmacokinetic study of saxagliptin in healthy Chinese subjects

21 January 2018

1 reference

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

21 January 2018

1 reference

Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Review of linagliptin for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

21 January 2018

1 reference

Recent advances in incretin-based therapies

21 January 2018

1 reference

Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients

21 January 2018

1 reference

Pramlintide in the treatment of type 1 and type 2 diabetes mellitus

21 January 2018

1 reference

Effect of lipid type on the binding of lipid vesicles to islet amyloid polypeptide amyloid fibrils

21 January 2018

1 reference

Synthesis and purification of amyloidogenic peptides.

21 January 2018

1 reference

Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function

21 January 2018

1 reference

Structures of rat and human islet amyloid polypeptide IAPP(1-19) in micelles by NMR spectroscopy

21 January 2018

1 reference

Pramlintide in the treatment of diabetes mellitus

21 January 2018

1 reference

Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin

21 January 2018

1 reference

Pramlintide and the treatment of diabetes: a review of the data since its introduction

21 January 2018

1 reference

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

Dapagliflozin for the treatment of type 2 diabetes

21 January 2018

1 reference

Sodium glucose cotransporter 2 and the diabetic kidney

21 January 2018

1 reference

Dapagliflozin: a review on efficacy, clinical effectiveness and safety.

21 January 2018

1 reference

SGLT inhibitors: a novel target for diabetes.

21 January 2018

1 reference

Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors.

21 January 2018

1 reference

Human glucagon receptor antagonists based on alkylidene hydrazides

21 January 2018

1 reference

Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor

21 January 2018

1 reference

Biaryl amide glucagon receptor antagonists

21 January 2018

1 reference

Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonists

21 January 2018

1 reference

Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.

21 January 2018

1 reference

Identification of alkylidene hydrazides as glucagon receptor antagonists.

21 January 2018

1 reference

Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes

21 January 2018

1 reference

Novel "second-generation" approaches for the control of type 2 diabetes

21 January 2018

1 reference

Selecting protein tyrosine phosphatases as drug targets

21 January 2018

1 reference

A Highly Selective and Potent PTP-MEG2 Inhibitor with Therapeutic Potential for Type 2 Diabetes

21 January 2018

1 reference

Antidiabetic effects of natural plant extracts via inhibition of carbohydrate hydrolysis enzymes with emphasis on pancreatic alpha amylase

21 January 2018

1 reference

Zinc complexes developed as metallopharmaceutics for treating diabetes mellitus based on the bio-medicinal inorganic chemistry

21 January 2018

1 reference

Vanadium treatment of type 2 diabetes: a view to the future

21 January 2018

1 reference

Leptin revisited: its mechanism of action and potential for treating diabetes

21 January 2018

1 reference

Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.

21 January 2018

1 reference

Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects

21 January 2018

1 reference

Glucokinase activators for diabetes therapy: May 2010 status report

21 January 2018

1 reference

Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.

21 January 2018

1 reference

Recent discovery of plant-derived anti-diabetic natural products

21 January 2018

1 reference

Chemical and pharmacological studies of Oplopanax horridus, a North American botanical

21 January 2018

1 reference

Medicinal chemistry of the anti-diabetic effects of momordica charantia: active constituents and modes of actions

21 January 2018

1 reference

Bauhinia purpurea Linn.: A Review of its Ethnobotany, Phytochemical and Pharmacological Profile

21 January 2018

1 reference

New and future immunomodulatory therapy in type 1 diabetes

21 January 2018

1 reference

β-cell preservation and regeneration for diabetes treatment: where are we now?

21 January 2018

1 reference

The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death

21 January 2018

1 reference

Recent advances in the therapeutic applications of pyrazolines.

21 January 2018

1 reference

Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetes.

21 January 2018

1 reference

Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial

21 January 2018

1 reference

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/FMC.13.13

1 reference

28 August 2017

1 reference